Conclina’ s main shareholder is a non-profit foundation, whose only investment is Conclina, and whose sole focus is providing free medical assistance via brigades to low income population in marginal regions outside Quito (Fundacion Metrofraternidad - 52% stake). The second shareholder, the employee’s foundation of the Instituto Ecuatoriano de Seguridad Social (IESS – 8% stake). Conclina is listed in Quito stock exchange (40% stake held by 1,915 shareholders).  

 The total project cost is estimated at US$ 26 million. The majority of the investment is for hospital CAPEX (80% including energy efficiency), and a lesser extent for diagnostics (20%).

The proposed IFC investment is a US$ 15 million A-Loan for IFC’s own account, which would finance 60% of the total project cost.

2020 COVID-19 Response - RSE Conclina

The Company is raising funds to finance potential liquidity shortfall to be faced as a result of the COVID-19 pandemic. The total Project cost is estimated to be US$14.3 million. IFC committed up to US$9.0 million in the form of an A-Loan to support the Project.

IFC financing supports Conclina in its direct and indirect response to the COVID-19 outbreak in Ecuador and will contribute to market resilience by supporting the continued operation of a high-quality provider in a market where the quality of care is limited. Supporting its clients’ capacity to sustain operations during this acute shock is critical to ensuring the availability of health care services in Quito, both during the current crisis period and after. That way IFC plays a critical countercyclical role and best positions the private sector to support the economic recovery process and the access to quality health services in the country.

 The proposed project is to be developed in Quito (Ecuador), within the existing facilities of Hospital Metropolitano. It counts with access to transportation routes and immediate access to Quito’s main avenue (Av. Mariana de Jesus).